-
Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential
Monday, August 29, 2016 - 10:39am | 274Read More...AstraZeneca plc (ADR) (NYSE: AZN) shares are currently trading at a discount to S&P 500 pharma companies. Argus’ John Eade believes the discount is too steep given the company’s pipeline potential. Eade upgraded the rating on the company to Buy with a price target of $38. Coping...
-
AstraZeneca Falls More Than 5% Following Q4 Print
Thursday, February 4, 2016 - 9:03am | 268Read More...Shares of AstraZeneca plc (ADR) (NYSE: AZN) were trading lower by more than 5 percent early Thursday morning after the company reported its fourth quarter results. AstraZeneca earned $0.94 per share in the fourth quarter on revenue of $6.39 billion. Wall Street analysts were expecting the...
-
What Are The Best-Selling Drugs Of 2014?
Friday, October 3, 2014 - 11:34am | 759Read More...What are the top-selling pharmaceutical drugs of the year? While 2014 is not yet over, it's possible to explore to answer to this question after making a few educated assumptions. According to research from IMS Health, a healthcare services, information and technology provider, the top...
